Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2022 Filed Mar 1, 2022 23:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000013 · wf-form4_164617866156651.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000013 · wf-form4_164617866156651.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 17, 2021 Filed May 17, 2021 20:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,045 | $6.62 | $20,157.90 |
DisclosureSEC source: 0001055726-21-000045 · wf-form4_162128322950395.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,791 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000045 · wf-form4_162128322950395.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000045 · wf-form4_162128322950395.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 859,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000045 · wf-form4_162128322950395.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 27,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001055726-21-000045 · wf-form4_162128322950395.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2031-05-13 F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Options to vest 100% on May 13, 2022. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 22,500 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001055726-21-000036 · wf-form4_161903896320284.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F4 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F4 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 4,083 | $8.54 | $34,868.82 |
DisclosureSEC source: 0001055726-21-000036 · wf-form4_161903896320284.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,136 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 22,500 | $8.57 | $192,825.00 |
DisclosureSEC source: 0001055726-21-000036 · wf-form4_161903896320284.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,219 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $8.49 to $8.66, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,500 | $2.40 | $54,000.00 |
DisclosureSEC source: 0001055726-21-000036 · wf-form4_161903896320284.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000025 · wf-form4_161559204229772.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000025 · wf-form4_161559204229772.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,500 | $9.60 | $33,601.05 |
DisclosureSEC source: 0001055726-21-000020 · wf-form4_161533459312789.xml · nonDerivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,552 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of restricted stock units granted by the issuer. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000020 · wf-form4_161533459312789.xml · derivative · entry 6 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000020 · wf-form4_161533459312789.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,500 | $9.18 | $32,134.90 |
DisclosureSEC source: 0001055726-21-000020 · wf-form4_161533459312789.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,385 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of restricted stock units granted by the issuer. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000020 · wf-form4_161533459312789.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000020 · wf-form4_161533459312789.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000015 · wf-form4_161438459117474.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 60,000 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001055726-21-000015 · wf-form4_161438459117474.xml · derivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-26 F1 · derivative.exercise_date: The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 26, 2021; 15,000 shares will vest on February 26, 2022; 15,000 shares will vest on February 26, 2023; 15,000 shares will vest on February 26, 2024. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 17,500 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001055726-20-000055 · wf-form4_160824994521394.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2021-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 17,500 | $10.71 | $187,351.50 |
DisclosureSEC source: 0001055726-20-000055 · wf-form4_160824994521394.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,219 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $10.54 to $10.83, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 17,500 | $4.56 | $79,800.00 |
DisclosureSEC source: 0001055726-20-000055 · wf-form4_160824994521394.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 844,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000039 · wf-form4_158957339225846.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock · 8,700 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 13,300 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001055726-20-000039 · wf-form4_158957339225846.xml · derivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2030-05-14 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 14, 2021. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,404 | $11.84 | $28,463.36 |
DisclosureSEC source: 0001055726-20-000033 · wf-form4_158931516303073.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,219 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| May 08, 2020 Filed May 8, 2020 22:19 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000026 · wf-form4_158897636187851.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. Read SEC document |
| May 08, 2020 Filed May 8, 2020 22:19 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000026 · wf-form4_158897636187851.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 829,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 20:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,500 | $11.14 | $38,990.00 |
DisclosureSEC source: 0001055726-20-000013 · wf-form4_158404559933910.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,610 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 60,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001055726-20-000013 · wf-form4_158404559933910.xml · derivative · entry 6 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-11 F4 · derivative.exercise_date: The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on March 11, 2020; 15,000 shares will vest on March 11, 2021; 15,000 shares will vest on March 11, 2022; 15,000 shares will vest on March 11, 2023. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000013 · wf-form4_158404559933910.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on March 11, 2021; 11,667 shares will vest on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000013 · wf-form4_158404559933910.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,500 | $9.32 | $32,620.00 |
DisclosureSEC source: 0001055726-20-000013 · wf-form4_158404559933910.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,110 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000013 · wf-form4_158404559933910.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2020 Filed Mar 9, 2020 20:20 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,500 | $18.00 | $63,000.00 |
DisclosureSEC source: 0001055726-20-000009 · wf-form4_158378519401805.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,944 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:20 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000009 · wf-form4_158378519401805.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares will vest on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares will vest on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares will vest on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares will vest on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:20 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000009 · wf-form4_158378519401805.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares will vest on March 8, 2021; 11,666 shares will vest on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:20 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000009 · wf-form4_158378519401805.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:20 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000009 · wf-form4_158378519401805.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares vested on March 5, 2020; 11,666 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 16,352 | $2.72 | $44,477.44 |
DisclosureSEC source: 0001055726-19-000049 · wf-form4_156477961645379.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,110 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 12, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.70 to $2.75, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 11, 2019 Filed May 13, 2019 19:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000038 · wf-form4_155777748753530.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,170 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. Read SEC document |
| May 11, 2019 Filed May 13, 2019 19:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000038 · wf-form4_155777748753530.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000030 · wf-form4_155743923408973.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,013 Underlying: Common Stock · 8,013 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 12,500 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001055726-19-000030 · wf-form4_155743923408973.xml · derivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-05-08 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest with respect to 100% of the shares on May 8, 2020. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000013 · wf-form4_155242471665422.xml · derivative · entry 6 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000013 · wf-form4_155242471665422.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 10, 2018; 11,667 shares vested on March 10, 2019; 11,666 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000013 · wf-form4_155242471665422.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 30,000 restricted stock units is as follows: 10,000 shares vested on March 9, 2017; 10,000 shares vested on March 9, 2018; 10,000 shares vested on March 9, 2019. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 30,000 restricted stock units is as follows: 10,000 shares vested on March 9, 2017; 10,000 shares vested on March 9, 2018; 10,000 shares vested on March 9, 2019. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 30,000 restricted stock units is as follows: 10,000 shares vested on March 9, 2017; 10,000 shares vested on March 9, 2018; 10,000 shares vested on March 9, 2019. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 30,000 restricted stock units is as follows: 10,000 shares vested on March 9, 2017; 10,000 shares vested on March 9, 2018; 10,000 shares vested on March 9, 2019. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000013 · wf-form4_155242471665422.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,000 restricted stock units was as follows: 5,334 shares vested on March 9, 2017; 5,333 shares vested on March 9, 2018; 5,333 shares vested on March 9, 2019. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,000 restricted stock units was as follows: 5,334 shares vested on March 9, 2017; 5,333 shares vested on March 9, 2018; 5,333 shares vested on March 9, 2019. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,000 restricted stock units was as follows: 5,334 shares vested on March 9, 2017; 5,333 shares vested on March 9, 2018; 5,333 shares vested on March 9, 2019. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,000 restricted stock units was as follows: 5,334 shares vested on March 9, 2017; 5,333 shares vested on March 9, 2018; 5,333 shares vested on March 9, 2019. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000013 · wf-form4_155242471665422.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 30,000 restricted stock units is as follows: 10,000 shares vested on March 9, 2017; 10,000 shares vested on March 9, 2018; 10,000 shares vested on March 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.